{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:35:12Z","timestamp":1784230512977,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2018\/362"],"award-info":[{"award-number":["CAN 2018\/362"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbrep.2024.101894","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T06:18:06Z","timestamp":1737008286000},"page":"101894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis"],"prefix":"10.1016","volume":"41","author":[{"given":"Jingmei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":false,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbrep.2024.101894_b1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.bbrep.2024.101894_b2","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2019-129331","article-title":"Safety and efficacy of midostaurin in combination with high-dose daunorubicin in 7+3 induction for acute myeloid leukemia with FLT3 mutation","volume":"134","author":"Deutsch","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbrep.2024.101894_b3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bbrep.2024.101894_b4","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10637-021-01151-0","article-title":"A critical appraisal of Japan\u2019s new drug approval process: a case study of FLT3-ITD inhibitor quizartinib","volume":"39","author":"Kidoguch","year":"2021","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.bbrep.2024.101894_b5","first-page":"257","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.bbrep.2024.101894_b6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bbrep.2024.101894_b7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bbrep.2024.101894_b8","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.18632\/oncotarget.7459","article-title":"Drug resistance in cancer: molecular evolution and compensatory proliferation","volume":"7","author":"Friedman","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bbrep.2024.101894_b9","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/prot.25368","article-title":"The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib","volume":"85","author":"Friedman","year":"2017","journal-title":"Proteins Struct. Funct. Bioinf."},{"issue":"15","key":"10.1016\/j.bbrep.2024.101894_b10","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1111\/febs.15209","article-title":"Deciphering the molecular mechanism of FLT3 resistance mutations","volume":"287","author":"Georgoulia","year":"2020","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b11","article-title":"The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"1877","author":"Friedman","year":"2022","journal-title":"Biochim. Et Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bbrep.2024.101894_b12","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1039\/D2CP05549J","article-title":"Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase","volume":"25","author":"Freire","year":"2023","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"7","key":"10.1016\/j.bbrep.2024.101894_b13","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.bbrep.2024.101894_b14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \u201cGatekeeper\u201d F691l mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b15","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01856-5","article-title":"Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbrep.2024.101894_b16","first-page":"2632","article-title":"The novel, irreversible FLT3 inhibitor FF-10101 demonstrates broad in vitro activity against FLT3 inhibitor resistance mutations","volume":"130","author":"Ferng","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2024.101894_b17","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107889","article-title":"Synergy and antagonism between azacitidine and FLT3 inhibitors","volume":"169","author":"Yang","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbrep.2024.101894_b18","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2019-124632","article-title":"FF-10101 retains potent inhibitory activities against resistant mutations to FLT3 inhibitors, newly identified in random mutagenesis screens","volume":"134","author":"Ishikawa","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbrep.2024.101894_b19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.bbrep.2024.101894_b20","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan","year":"2022","journal-title":"Blood Cancer J."},{"issue":"58","key":"10.1016\/j.bbrep.2024.101894_b21","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"10.1016\/j.bbrep.2024.101894_b22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drup.2008.12.001","article-title":"Mechanisms of resistance to FLT3 inhibitors","volume":"12","author":"Chu","year":"2009","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.bbrep.2024.101894_b23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2009.04.001","article-title":"FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML","volume":"12","author":"Weisberg","year":"2009","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-09048-5","article-title":"Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model","volume":"12","author":"Lindstr\u00f6m","year":"2022","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bbrep.2024.101894_b25","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1021\/acs.jmedchem.9b00223","article-title":"Identification of pyrrolo[2,3]pyrimidine-based derivatives as potent and orally effective fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","volume":"62","author":"Yuan","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbrep.2024.101894_b26","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: Challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bbrep.2024.101894_b27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082059","article-title":"Drug resistance missense mutations in cancer are subject to evolutionary constraints","volume":"8","author":"Friedman","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1745-6150-7-12","article-title":"Domain enhanced lookup time accelerated BLAST","volume":"7","author":"Boratyn","year":"2012","journal-title":"Biol. Direct"},{"issue":"14","key":"10.1016\/j.bbrep.2024.101894_b29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/gkf436","article-title":"MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform","volume":"30","author":"Katoh","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"11\u201312","key":"10.1016\/j.bbrep.2024.101894_b30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: A key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"issue":"7","key":"10.1016\/j.bbrep.2024.101894_b31","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26174","article-title":"A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance","volume":"96","author":"Joshi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrep.2024.101894_b32","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27096","article-title":"The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib","author":"Joshi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"D1","key":"10.1016\/j.bbrep.2024.101894_b33","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"48","key":"10.1016\/j.bbrep.2024.101894_b34","doi-asserted-by":"crossref","first-page":"13726","DOI":"10.1073\/pnas.1610626113","article-title":"Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors","volume":"113","author":"Richards","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.bbrep.2024.101894_b35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bbrep.2024.101894_b36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102238","article-title":"Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib","volume":"298","author":"Oruganti","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbrep.2024.101894_b38","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107826","article-title":"Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models","volume":"169","author":"Lindstr\u00f6m","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbrep.2024.101894_b39","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107889","article-title":"Synergy and antagonism between azacitidine and FLT3 inhibitors","volume":"169","author":"Yang","year":"2024","journal-title":"Comput. Biol. Med."},{"issue":"11","key":"10.1016\/j.bbrep.2024.101894_b40","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1634\/theoncologist.2019-0656","article-title":"Long-term response to intermittent binimetinib in patients with NRAS-mutant melanoma","volume":"25","author":"Matter","year":"2020","journal-title":"Oncol."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b41","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bbrep.2024.101894_b42","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101894_b43","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1563","article-title":"Computational studies of protein\u2013drug binding affinity changes upon mutations in the drug target","volume":"12","author":"Friedman","year":"2021","journal-title":"WIREs Comput. Mol. Sci."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824002589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824002589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:11:23Z","timestamp":1773864683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580824002589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"alternative-id":["S2405580824002589"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101894","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101894"}}